Pharma

Your Article Summary

See Latest Articles

Novogen Cash Reserves $25.4M, Phenoxodiol Receives US FDA Clearance for Phase III Human Trial
Corporate News Releases - The Healthcare Sales & Marketing Network, 08/28/06

Pharmaceutical company Novogen Limited, has ended the 2005/06 financial year with solid cash reserves and US Food and Drug Administration (FDA) clearance for the final phase of human clinical testing of its lead anti-cancer drug, phenoxodiol. Revenue for the year ended 30 June, 2006, was $13.9 million, a 3.2 percent improvement over the previous corresponding period of $13.4 million

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial
European Heart Journal, 06/09/09

Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841
Journal of Clinical Oncology, 06/15/09

Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy
Trials, 06/05/09

See All of Drug Trials